Compare Novo Nordisk A/S (NVO) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs 10X Genomics Inc — how do they compare? Novo Nordisk A/S trades at $38.52 (market cap $165.31B), while 10X Genomics Inc trades at $81.89 (market cap $10.07B). The key difference: Novo Nordisk A/S is far larger — about 16.4× 10X Genomics Inc's market cap, and Novo Nordisk A/S pays a 4.71% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and 10X Genomics Inc for 92 Days on average.
| NVO | TXG | |
|---|---|---|
Market Cap | $165.31B | $10.07B |
Volume | 11,432,838 | 5,657,286 |
Sector | Health | Health |
52-Week High | $63.98 | $97.74 |
52-Week Low | $35.29 | $11.48 |
Typical Hold Time | 116 Days | 92 Days |
Enterprise Value | $179.56B | $9.59B |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with a bullish technical signal supported by oscillators like RSI at 20.06 (buy signal). The company shows strong fundamentals with a P/E of 9.66, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights pipeline developments, including a Wegovy pill study showing continued weight loss and a $4 billion licensing deal, though an FDA delay for a hemophilia drug poses a near-term headwind.
The outlook remains positive with a consensus price target of $44.67, implying 17% upside, driven by robust profitability and growth in GLP-1 therapies. Risks include competitive pressure from Eli Lilly, regulatory delays, and reliance on obesity/diabetes drugs. Analyst sentiment is bullish (59% buy ratings), but investors should monitor execution amid high expectations.
TXG trades at $76.10, down 5.65% on the day, reflecting a bearish technical trend. The company reported revenue of $642.82M for 2025 with a net loss of $43.54M, though it has consistently beaten quarterly EPS estimates. Recent news highlights strong demand for its Atera spatial biology platform and a patent victory. The stock faces resistance near $77 and support at $72.
The outlook is mixed; strong product demand and improving margins offer upside, but persistent losses and high valuation ratios pose risks. Analyst consensus is divided, with a $74.30 price target slightly below the current price, indicating cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
